Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
The benefit of immunochemotherapy in treating resectable locally advanced non-small cell lung cancer (NSCLC) is not well established. Here, we report a case of resectable stage III NSCLC treated with neoadjuvant immunotherapy combined with chemotherapy before surgery. A 61 years old man was admitted...
Guardado en:
Autores principales: | Zheng Yuan, Zhu Wei, Huang Xinjie, Lin Dongqun, Lin Yu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cef4b757c5844e30ab016ce38b309643 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Ze-Rui Zhao, et al.
Publicado: (2021) -
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019) -
Influence of correction of nutritive deficiency on the effectiveness of neoadjuvant chemotherapy in patients with locally advanced gastric cancer
por: Nadezhda A. Brish, et al.
Publicado: (2021) -
Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
por: Kamil D. Dalgatov, et al.
Publicado: (2021) -
Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer
por: Ziyi Liu, et al.
Publicado: (2021)